FDA Issues Complete Response Letter for Satsuma ’s STS101

TOKYO and KAGOSHIMA, Japan, January 18, 2024– Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, Chairman and President: Ryoichi Nagata, M.D., Ph.D.,“SNBL”) announced today that its wholly-owned US subsidiary, Satsuma...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news